OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
3205$56.4056

Sagittarius Life Science Corp

Food ProcessingVerified

Sagittarius Life Science Corp has a strong liquidity position, with a current ratio of 31.84, indicating a significant excess of current assets over current liabilities. The company's cash and equivalents amount to TWD 151.55 million, which is 14.5% of total assets, and its debt-to-equity ratio is 0.0, suggesting no leverage in its capital structure. The price-to-book ratio of 3.66 implies that the market values the company at a premium to its book value, while the price-to-tangible-book ratio is identical, indicating no intangible asset premium. Profitability metrics show a challenging performance, with a return on equity (ROE) of -4.76% and a return on assets (ROA) of -4.62%, both significantly below the industry median for Food Processing. The company reported a net loss of TWD 49.56 million and an operating loss of TWD 58.51 million, with a gross profit of TWD 57.71 million on revenue of TWD 346.08 million. These figures suggest a low margin environment and operational inefficiencies. The company's revenue is concentrated in its core health product segments, with no disclosed geographic breakdown. However, the company operates in both domestic and international markets, including the rest of Asia and the Americas. The lack of segment-specific revenue data limits the ability to assess geographic or product concentration risk. Looking ahead, the company's revenue outlook is uncertain, with no disclosed growth trajectory in the financial snapshot. The operating cash flow is negative at TWD -36.05 million, and free cash flow is also negative at TWD -40.06 million, indicating a lack of cash generation from operations. Capital expenditures are minimal at TWD -404,000, suggesting limited investment in growth. Risk factors include the company's negative net income and operating income, which could impact its ability to sustain operations without external financing. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative cash flows and profitability metrics suggest potential long-term sustainability concerns. Recent events include the latest financial filing, which shows a continued operating loss and negative cash flows. No recent transcripts or filings beyond the financial snapshot are available to assess management commentary or strategic direction.

30-day price · 3205-1.70 (-3.0%)
Low$51.80High$67.00Close$54.80As of12 May, 00:00 UTC
Profile
CompanySagittarius Life Science Corp
Ticker3205.TWO
SectorConsumer Non-Cyclicals
BusinessFood & Beverages
Industry groupFood & Beverages
IndustryFood Processing
AI analysis

Business. Sagittarius Life Science Corp is a Taiwan-based company engaged in the research, development, production, and sales of health products, including nutrition formulations, natural food, probiotics, beauty care ingredients, and health supplies, with distribution in domestic and international markets.

Classification. Sagittarius Life Science Corp is classified under the Consumer Non-Cyclicals economic sector, Food & Beverages business sector, and Food Processing industry, with a classification confidence of 0.92.

Sagittarius Life Science Corp has a strong liquidity position, with a current ratio of 31.84, indicating a significant excess of current assets over current liabilities. The company's cash and equivalents amount to TWD 151.55 million, which is 14.5% of total assets, and its debt-to-equity ratio is 0.0, suggesting no leverage in its capital structure. The price-to-book ratio of 3.66 implies that the market values the company at a premium to its book value, while the price-to-tangible-book ratio is identical, indicating no intangible asset premium. Profitability metrics show a challenging performance, with a return on equity (ROE) of -4.76% and a return on assets (ROA) of -4.62%, both significantly below the industry median for Food Processing. The company reported a net loss of TWD 49.56 million and an operating loss of TWD 58.51 million, with a gross profit of TWD 57.71 million on revenue of TWD 346.08 million. These figures suggest a low margin environment and operational inefficiencies. The company's revenue is concentrated in its core health product segments, with no disclosed geographic breakdown. However, the company operates in both domestic and international markets, including the rest of Asia and the Americas. The lack of segment-specific revenue data limits the ability to assess geographic or product concentration risk. Looking ahead, the company's revenue outlook is uncertain, with no disclosed growth trajectory in the financial snapshot. The operating cash flow is negative at TWD -36.05 million, and free cash flow is also negative at TWD -40.06 million, indicating a lack of cash generation from operations. Capital expenditures are minimal at TWD -404,000, suggesting limited investment in growth. Risk factors include the company's negative net income and operating income, which could impact its ability to sustain operations without external financing. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative cash flows and profitability metrics suggest potential long-term sustainability concerns. Recent events include the latest financial filing, which shows a continued operating loss and negative cash flows. No recent transcripts or filings beyond the financial snapshot are available to assess management commentary or strategic direction.
Key takeaways
  • Sagittarius Life Science Corp has a strong liquidity position with a current ratio of 31.84 and no debt.
  • The company is unprofitable, with a net loss of TWD 49.56 million and an operating loss of TWD 58.51 million.
  • The company's price-to-book ratio of 3.66 suggests a premium valuation despite negative earnings.
  • The company's cash flows are negative, with operating cash flow at TWD -36.05 million and free cash flow at TWD -40.06 million.
  • The company's risk assessment indicates low liquidity and dilution risk, but its negative profitability metrics raise concerns about long-term sustainability.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyTWD
Revenue$346.1M
Gross profit$57.7M
Operating income-$58.5M
Net income-$49.6M
R&D
SG&A
D&A
SBC
Operating cash flow-$36.0M
CapEx-$404.0k
Free cash flow-$40.1M
Total assets$1.07B
Total liabilities$29.4M
Total equity$1.04B
Cash & equivalents$151.5M
Long-term debt$385.0k
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$346.1M-$58.5M-$49.6M-$40.1M
FY-1$467.8M-$61.6M-$48.5M-$41.0M
FY-2$440.5M-$64.4M-$55.0M-$46.8M
FY-3$529.1M-$82.2M-$74.2M-$59.7M
FY-4$587.6M-$90.0M-$86.4M-$74.7M
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$1.07B$1.04B$151.5M
FY-1$519.8M$408.3M$83.8M
FY-2$664.7M$514.7M$133.9M
FY-3$579.1M$441.8M$189.5M
FY-4$675.7M$516.8M$255.7M
PeriodOCFCapExFCFSBC
FY0-$36.0M-$404.0k-$40.1M
FY-1-$44.5M-$3.8M-$41.0M
FY-2-$69.4M-$2.0M-$46.8M
FY-3-$52.9M-$1.1M-$59.7M
FY-4-$29.2M-$8.4M-$74.7M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0$39.6M-$13.5M-$11.4M-$9.8M
FQ-1$92.9M-$14.5M-$6.8M-$5.0M
FQ-2$112.7M-$14.9M-$15.7M-$12.5M
FQ-3$100.9M-$15.7M-$15.7M-$12.7M
FQ-4$117.9M-$8.5M-$8.1M-$4.6M
FQ-5$114.5M-$19.0M-$14.7M-$13.4M
FQ-6$118.3M-$18.6M-$16.4M-$13.5M
FQ-7$117.0M-$15.4M-$9.3M-$7.2M
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0$1.07B$1.04B$151.5M
FQ-1$1.11B$1.05B$163.6M
FQ-2$1.14B$1.06B$141.1M
FQ-3$499.9M$405.0M$76.2M
FQ-4$519.8M$408.3M$83.8M
FQ-5$581.3M$461.9M$105.5M
FQ-6$635.2M$510.0M$125.2M
FQ-7$619.5M$494.0M$140.2M
PeriodOCFCapExFCFSBC
FQ0-$36.0M-$404.0k-$9.8M
FQ-1-$14.8M-$404.0k-$5.0M
FQ-2-$14.9M-$321.0k-$12.5M
FQ-3-$7.4M-$315.0k-$12.7M
FQ-4-$44.5M-$3.8M-$4.6M
FQ-5-$33.9M-$3.7M-$13.4M
FQ-6-$20.2M-$1.5M-$13.5M
FQ-7-$18.1M-$904.0k-$7.2M
Valuation
Market price$56.40
Market cap$3.81B
Enterprise value$3.66B
P/E
Reported non-GAAP P/E
EV/Revenue10.6
EV/Op income
EV/OCF
P/B3.7
P/Tangible book3.7
Tangible book$1.04B
Net cash$151.2M
Current ratio31.8
Debt/Equity0.0
ROA-4.6%
ROE-4.8%
Cash conversion73.0%
CapEx/Revenue-0.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Food Processing · cohort 6 companies
Metric3205Activity
Op margin-16.9%3.3% medp25 2.5% · p75 4.5%bottom quartile
Net margin-14.3%3.0% medp25 1.5% · p75 6.7%bottom quartile
Gross margin16.7%24.0% medp25 20.2% · p75 35.3%bottom quartile
R&D / revenue0.8% medp25 0.5% · p75 2.3%
CapEx / revenue-0.1%5.2% medp25 4.8% · p75 5.7%bottom quartile
Debt / equity0.0%33.5% medp25 29.1% · p75 81.5%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-11 00:14 UTC#73f38f00
Market quoteclose TWD 56.40 · shares 0.07B diluted
no public URL
2026-05-11 00:14 UTC#cbf4709d
Source: analysis-pipeline (hybrid)Generated: 2026-05-11 00:16 UTCJob: 948436af